Drug Type Small molecule drug |
Synonyms SY 5609, SY-5102 |
Target |
Action inhibitors |
Mechanism CDK7 inhibitors(Cyclin-dependent kinase 7 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC23H26F3N6OP |
InChIKeyJDJOUBVVSQDIRC-AWEZNQCLSA-N |
CAS Registry2417302-07-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 1 | United States | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Australia | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Canada | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Denmark | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Germany | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Italy | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Poland | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Spain | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | Taiwan Province | 22 Oct 2021 | |
Metastatic Colorectal Carcinoma | Phase 1 | United Kingdom | 22 Oct 2021 |
Phase 1 | Hormone receptor positive HER2 negative breast cancer HR positive | HER2 Negative | 14 | iarubiueih(fwulyeevzh) = xfpwezxurf behuzsmsaj (uqlktpwfwb ) View more | Positive | 31 May 2023 | ||
Phase 1 | 87 | (SLIs) | - | Positive | 26 May 2023 | ||
gemcitabine+SY-5609 (SLIs) | xzzedmrsqj(chqjswxwoj) = rxcdylltxt zopjjovxaf (vzjldnbavv ) | ||||||
Phase 1 | - | zztxkmqmfl(ncomddbcgw) = lmeymztytx lgklnztjii (bgnbxdsjoj ) | - | 02 Jun 2022 | |||
Phase 1 | 51 | zetjucalyo(ensugkyvqi) = (≥20%) included nausea, diarrhea, fatigue, decreased appetite, and thrombocytopenia; majority were low grade (1/2) and reversible jdylcxslsz (yyrlbdzbnt ) | Positive | 20 Sep 2021 |